AAV APEX suite
An engineered suite of tools for end-to-end AAV production
Today, our cell lines deliver high yield and quality, significantly reducing AAV manufacturing COGS, but we know that’s only part of the challenge. We are developing the next generation of cell lines designed not only to enhance efficiency but to enable gene therapies previously deemed unfeasible. Stay tuned as we redefine what’s possible in AAV production.
OVERVIEW
Powered by VectorSelect
Our VectorSelect Platform is powering the development of high yield AAV production cell lines — including our own AAV Apex Suite. The same platform enables bespoke cell line optimization.
Perturbation discovery
Genome scale screens capturing genotype-to-phenotype relationships for AAV production.
.svg)
Discovery and validation of novel genetic pathways that enhance yield and quality.
Engineered cell lines leverage high impact pathways to achieve superior performance.
.svg)
Combining perturbations from complementary pathways is actively informing future product development.
Process discovery
.svg)
Data across 300+ production runs, 3+ scales and 9+ process parameters.
.svg)
Discovery and validation of novel metabolic pathways that enhance AAV yield and quality.
.svg)
Robust, transfer-ready processes supporting our cell lines, using commercially available consumables.
.svg)
These insights are actively guiding future product development, including new solutions beyond cell lines.
TRANSIENT PRODUCTION
overview
We offer transient cell line products that have been independently confirmed by leading pharmaceutical companies and CDMOs across multiple scales, serotypes and therapeutic payloads, at high titer and quality.
Suspension-adapted HEK293 clonal cell lines
- Suspension-adapted in chemically defined media.
- Fast recovery, fast doubling time, and non-aggregated.
- Documented monoclonality.
- High quality research grade available, GMP grade coming soon.
High titers across multiple AAV serotypes
Independently confirmed by partners, our cell lines deliver consistently high yield, high quality titers exceeding E15 vg/L across a range of AAV serotypes, using a commercially available plasmid system and a GFP payload.
.svg)